{"ticker": {"uuid": "ad296375-ad76-47f2-a3e0-c852c3af3475", "symbol": "ALXO", "name": "Alx Oncology Holdings", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations", "summary": "Shelly Wong, SVP of ALX Oncology Holdings (ALXO), sold 1,404 shares of common stock at a weighted average price of $2.04 per share. This transaction was conducted to fulfill tax obligations related to the vesting of her restricted stock units. After the sale, Wong directly holds ", "url": "https://www.stocktitan.net/sec-filings/ALXO/form-4-alx-oncology-holdings-inc-insider-trading-activity-f5929062a503.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:56", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO - Alx Oncology Holdings Inc Options", "summary": "This article provides a detailed financial overview of Alx Oncology Holdings Inc. (ALXO), including its latest stock price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as insider and institutional ownership, pr", "url": "https://finviz.com/stock?t=ALXO&ta=1&p=d&ty=oc&b=2&r=m6&ov=list_strike&s=1", "source_name": "Finviz", "published_at": "2026-07-02T09:09:47", "published_display": "02 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com", "summary": "ALX Oncology Holdings Inc. has announced Scott Garland as the new Chairman of its Board of Directors and Michael Listgarten as General Counsel. Garland, with over 30 years in biopharmaceuticals, succeeds co-founder Corey Goodman, while Listgarten brings extensive legal experience", "url": "https://ng.investing.com/news/stock-market-news/alx-oncology-names-scott-garland-chairman-adds-general-counsel-93CH-2579990", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T09:40:05", "published_display": "01 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology's Corey Goodman resigns as Chairman and director", "summary": "Corey Goodman has resigned from his roles as Chairman and a board member of ALX Oncology, effective June 29, 2026, due to personal reasons. The company stated that his resignation was not related to any disagreements regarding operations, policies, or practices. His replacement i", "url": "https://www.tradingview.com/news/tradingview:c0b3beb55333c:0-alx-oncology-s-corey-goodman-resigns-as-chairman-and-director/", "source_name": "TradingView", "published_at": "2026-07-01T08:10:25", "published_display": "01 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules", "summary": "ALX Oncology Holdings Inc. announced an inducement stock option grant to its new General Counsel, Michael Listgarten, for 500,000 shares. This grant was made on June 29, 2026, as an inducement for his employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules/2376280/amp", "source_name": "The Manila Times", "published_at": "2026-07-01T04:56:00", "published_display": "01 Jul 2026 04:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology replaces its chairman and adds a new general counsel", "summary": "ALX Oncology (Nasdaq: ALXO) has announced significant leadership changes, appointing Scott Garland as the new Chairman of the Board and Michael Listgarten as General Counsel, effective immediately. Garland succeeds co-founder Corey Goodman, who is stepping down after over a decad", "url": "https://www.stocktitan.net/news/ALXO/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-ctxi38ps1d12.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:09:10", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair", "summary": "ALX Oncology Holdings Inc. (NASDAQ: ALXO) has announced a leadership transition, with co-founder and long-time Chairman Corey Goodman, Ph.D., stepping down for personal reasons effective June 29, 2026. Scott Garland, an existing independent director, has been appointed as the new", "url": "https://www.stocktitan.net/sec-filings/ALXO/8-k-alx-oncology-holdings-inc-reports-material-event-9816e010ee3d.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:10:25", "published_display": "30 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Appoints Scott Garland as Board Chairman", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alx-oncology-appoints-scott-garland-122354790.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:23:54+00:00", "published_display": "30 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel", "summary": "ALX Oncology Holdings Inc. has announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel. Mr. Garland, who has served on the board since November 2022, succeeds co-founder Corey Goodman, Ph.D., who is stepping down", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319582/0/en/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-michael-listgarten-as-general-counsel.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:09:51", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology grants 500,000-share option to new general counsel", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZ3ZXdmxFMTUyV2lWOFh5UUJLNlNpenV3T20zd1p0Tm9IMnhYSTBXMXB0RWhvaGlvTDJsMGQwN0hYUFh0OWRjSDFycThnSVFvLVYxRmw3UGVnY0FZa1lsQjFRZGpoXzBjdmZaTlVpc0VCXzA3Wkt1RDBnbTJtYjJtRmVKT0U1N0pWNm5HOE9YNHkyc2tQRVRkQlVWZkplZmdpcnpLay1hTDA4LUwwT1daT2Jpd1NsMnBGcUVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Index", "summary": "ALX Oncology Holdings Inc. (NasdaqGS: ALXO) has been added to the Russell 3000E Index, as announced on June 29, 2026. This inclusion is part of several recent additions for the company to various Russell indices, including the Russell 2000, Russell 2000 Growth Benchmark, Russell ", "url": "https://www.marketscreener.com/news/alx-oncology-holdings-inc-nasdaqgs-alxo-added-to-russell-3000e-index-ce7f5fdedd81f226", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:09:51", "published_display": "29 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc. (ALXO) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for ALX Oncology Holdings Inc. (ALXO) on NASDAQ, showing its current price of $2.23 and a 9.30% increase. The page also includes sections for analyst ratings (currently unavailable), earnings information, and promotional content for", "url": "https://stockstotrade.com/quote/ALXO", "source_name": "StocksToTrade", "published_at": "2026-06-29T18:41:37", "published_display": "29 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNY0VSZUJqcmpuS0c4NFJnRm9KczJLSDdCZnVGY05OdHM1MkdmbjR3eGt4NVFzRUZmblpBbU9HX3l0UThZaDdIWjhuNFR3UFdmc3NWUDRxTERrSmZfbWhTdW5ELWkyeEhRR1NEZGpBR3V1U0JXN1g5cXN2TWdic0JmNWNQYjNFQlRXV3hqaEFCS3BqOFF6V2h4VHFWZU5ETV9PWnpFZVFOS1lzbXVJZURKekk1cm5kX2hnSGkzMnlnM0JabGZDSVYtU2cxVmVrVzFPREVJSlJKaVY?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:14:00+00:00", "published_display": "29 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ALX Oncology Holdings Inc. \u2013 NASDAQ:ALXO", "summary": "This article provides the \"Price to book forward\" for ALX Oncology Holdings Inc. (NASDAQ: ALXO). It indicates that the market is closed with no current trades. The information is presented within the context of the company's financial data on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:40:18", "published_display": "29 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell Microcap Index", "summary": "ALX Oncology Holdings Inc. (NasdaqGS:ALXO) has been added to the Russell Microcap Index. The company is a clinical-stage biotechnology firm developing therapies for cancer, with its lead product candidate, evorpacept, currently in multiple clinical trials. This inclusion in the i", "url": "https://www.marketscreener.com/news/alx-oncology-holdings-inc-nasdaqgs-alxo-added-to-russell-microcap-index-ce7f5fdedd89f627", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:50", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline", "summary": "ALX Oncology Holdings Inc. (ALXO) stock saw an 11.73% increase, driven by upcoming participation in the 2026 Jefferies Global Healthcare Conference. The company will showcase its clinical-stage oncology pipeline, particularly lead CD47 blocker evorpacept and EGFR-targeted ADC ALX", "url": "https://www.timothysykes.com/news/alxoncologyholdingsinc-alxo-news-2026_06_28/", "source_name": "Timothy Sykes", "published_at": "2026-06-28T14:10:25", "published_display": "28 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO Rises As ALX Oncology Showcases Pipeline At Jefferies", "summary": "ALX Oncology Holdings Inc. (ALXO) surged by 11.73% after showcasing its clinical-stage pipeline, including lead CD47 blocker evorpacept and EGFR-targeted ADC ALX2004, at the 2026 Jefferies Global Healthcare Conference. Despite being a clinical-stage biotech with negative profitab", "url": "https://stockstotrade.com/news/alxoncologyholdingsinc-alxo-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T12:10:25", "published_display": "28 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ALX Oncology Holdings Inc. \u2013 NASDAQ:ALXO", "summary": "This article provides a brief mention of the \"Price to sales forward\" metric for ALX Oncology Holdings Inc. (NASDAQ: ALXO). It appears to be a stub or a financial data point from TradingView, lacking detailed analysis or contextual information. The content primarily consists of n", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:10:25", "published_display": "28 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Secures New $50 Million Loan Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQU0NyRkozeXAtWGJGYmU2dmx5QzhhV3Y2b2xrN2xEMmxMMWd6MTdSaEdxd29tMTAzMmdnbE5WeVNLaTh1V1M0YS1uRlpXdmpkRVZUdWo5aGZ4Tm5wZnVLWXNRQTR1QVJQNzFFOWpHTFVVMkVEVHREZlhGSS0tcXhxVTB6ZkhqSkF4SmxzLUtMcVJvQ0hWLVFRY04tOGJZbmN6MGF6QW1rdFBfUW40aDQ5eUdLM00yOHFST3pSdm9SYVFNQ3I1aEp1bU95TmxQNG14UFE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing", "summary": "Alx Oncology Holdings has entered into a Loan and Security Agreement with HSBC Ventures, according to an SEC filing. This agreement was made on June 25, 2026. The news was reported by Reuters via TradingView.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Y13D:0-alx-oncology-holdings-enters-loan-and-security-agreement-with-hsbc-ventures-on-june-25-2026-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-26T22:10:51", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility", "summary": "ALX Oncology Holdings Inc. (NASDAQ: ALXO) has secured a new multi-tranche term loan facility of up to $50 million with HSBC Ventures USA Inc. The company immediately drew $10 million to refinance existing debt and has access to an additional $40 million, with portions contingent ", "url": "https://www.stocktitan.net/sec-filings/ALXO/8-k-alx-oncology-holdings-inc-reports-material-event-1ecb3f3d0d77.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:10:51", "published_display": "26 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings, Inc. Actuals & Estimates (NASDAQ:ALXO)", "summary": "This article provides an overview of ALX Oncology Holdings Inc. (ALXO) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent earnings and revenue f", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T03:09:44", "published_display": "26 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for ALX Oncology Holdings Inc. (ALXO) stock, including analyst ratings, EPS and revenue metrics, and historical price performance. It covers frequently asked questions regarding the stock's current price, volatility, market cap, e", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:42:29", "published_display": "25 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology: Rebuilding From Critical Setbacks (NASDAQ:ALXO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNZmlNU0ZpZ2lYRkFoWVlaaXE0YjY3bzdqS0FqbVEtX1pzZDQ5UUNRaXJrbWtrREJsM3J0dkNSUzFyZnA0Sm1JUk13RkFqTmNORmRwX05mUmxqNHRGdTNsSGE1cS0ybjhJeDBYNThZWFkySlUzOWZwSVpIc3cxMTE2RVRzbGt6VDZiRjJTLVo2Z2I?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "ALX Oncology Holdings Inc (ALXO) has a weak financial status and low operating efficiency, ranking 367 out of 389 in the Biotechnology & Medical Research industry with a financial score of 5.40. The article notes that relevant financial data for Quality of Earnings, Operational E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T03:40:08", "published_display": "19 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ALX Oncology Holdings Inc's (ALXO) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports no data available for past stock splits. The piece essentially serves as a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:39", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Institutional Confidence", "summary": "ALX Oncology Holdings Inc (ALXO) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.46%, marking a 62.05% decrease quarter-over-quarter. James Simons", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:10:39", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for ALX Oncology Holdings Inc (ALXO), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It lists the current stock price, market capitalization, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:10", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of ALX Oncology Holdings Inc's (ALXO) shareholder structure, listing major shareholders by proportion and category (e.g., private equity, investment advisor). It also presents institutional shareholding data over several quarters and rec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:10", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ALX Oncology Holdings Inc (ALXO), noting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $3.00 for ALXO, with most recommending a \"Buy\" tr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T03:11:41", "published_display": "17 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit", "summary": "ALX Oncology Holdings Inc. stockholders voted on June 10, 2026, to re-elect Class II directors Daniel Curran, Rekha Hemrajani, and Chris Takimoto, to serve until the 2029 annual meeting. Shareholders also approved the compensation of the company's named executive officers on an a", "url": "https://www.stocktitan.net/sec-filings/ALXO/8-k-alx-oncology-holdings-inc-reports-material-event-c96ebd04b635.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:48", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO: All voting proposals passed and clinical programs advanced, with key data expected soon", "summary": "ALX Oncology Holdings Inc. (ALXO) announced that all voting proposals, including director elections, executive compensation, and auditor ratification, were approved at their 2026 Annual General Meeting. The company also reported progress in its clinical programs, evorpacept and A", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3547239:0-alxo-all-voting-proposals-passed-and-clinical-programs-advanced-with-key-data-expected-soon/", "source_name": "TradingView", "published_at": "2026-06-10T20:39:31", "published_display": "10 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs", "summary": "", "url": "https://finance.yahoo.com/m/a70c78b0-10ce-3efa-967b-1e607d846d0e/alx-oncology-targets-key.html", "source_name": "MarketBeat", "published_at": "2026-06-04T03:02:13+00:00", "published_display": "04 Jun 2026 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (ALXO) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/0df0ab5d-7869-36f1-b2ee-27fb57e5583f/alx-oncology-%28alxo%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-01T17:23:59+00:00", "published_display": "01 Jun 2026 17:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alx-oncology-present-2026-jefferies-120000644.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdk9CcHA2Sk9GemZFUl94bUpzZUUyRnZhcDNtSkVHeGlSdFRESEpSeXJiYWNneXM3cnlMUlFKekZ2QXl4NEY1Ynh6ZFRNY2lXOUdHdE5LWExQWEctV3pqY0hqVUMxUU1uUENhWTBUb2xrczVqMU9SSDR6SE5YNS1oelNQRFF2RTJXd1hCVEd4cXJMNGZmUWFNWWhVYzlIUGlHanVNQkE3MUw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/a7a588b2-ec18-379c-be1c-8a1f4ea9d37d/alx-oncology-holdings-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-09T12:30:00+00:00", "published_display": "09 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/62d32ea5-e650-393e-8cd4-c3e746bc928d/alx-oncology-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-08T14:57:21+00:00", "published_display": "08 May 2026 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX ONCOLOGY ($ALXO) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQaGJDcmwzM1JRZFhBT1ZRTXE1WmxGN3BLTFN4VEVVRTJpNzVYU0FaVzE3VGNVU1ZjcGJ3Z0VHZ3NUS1ZaZ2lMNV82Qmtla1FtVGY0YXVybDZvMlJ5aGVMMEZiMElHZlJJbVFnT2R1RXdfTldvVlVvZFlCeTRpaWlBaE8zUjF6ZFRSbGtzdkVB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wells Fargo initiates ALX Oncology stock with overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTXJwZEJxRVgwcUxhQ25JakFPRnhjczY4ald5UUpwVm5qVHc2amtfNTFETUwtUlFta2VySjgzU1FpSUppdXRIZnJUcXlRYlZGenhSRmJkbFlNdzY4TUo0SEdNRjVVeXBDYVJ4d3Q0ODNQT09FTS1UVEdwcjg2aGJ3VXI1WjJUZ3I5ZDlDOWU5VFdoTjRVWmxrX25EWjZOZTQ2elk4WkdmYjRvTklTeTNva1hiRVlReTVlQUFfT0UyZ2Q?oc=5", "source_name": "Investing.com", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNVXJHbFRMdjdBaXlGZmNSUDYwbzZkb213MlZYQldkZmFrdEtHbFRDeV91U0doUmNQMV9TeUE5MDB0dWxidWJvWXkwWFZhY0c5RzhnWTB5ZEdEMzFvMUVHWXg5dHNIZnpVRTZzX1hrOXJsVnRGTWo2THZBd3R5RHZBVC1zcm5ON19KWnBGd0o0ek1qemhRemVxLWRfTTdiTGY2SWRnODJ2OGxPQWt4c0VQdzA0RmVPQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Announces Pricing of Underwritten Offering", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNY2tCa20yZnRVeDNhM2w4V0Y2QW9UVDBjMmNXN01oTVZTRVgwX19WaEtBQmp3dlhXZGVPMjVsQTBEcEZGdGJzMVk1Y3k4X1JsMEt1NWdjMHRMZjRlcDR4THQ4dHFiaGpNTDZYSlA3RFEtU0dLS1RtMlF1Q0dBeDdDUkZTUERsREZ4TDYw?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (ALXO) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE95UTRQcWt3SWpkZ3pRNjRQZEV3WTgycUN1V2YxLWUzbVNtTndTZkVFSXg2Wnl4dVB4ME1EYVZMZ2lMZ2Nna25FdlZ1eDNaNDRfZ1oxUUdocUNaRmt6LV85OVZfeW1JT2FL?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T15:48:12+00:00", "published_display": "09 Jul 2025 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alx Oncology Holdings (ALXO) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBLXy16N0ZLcUtaaHZFWFgtbE9yZ2x5UDB5QVh0c0NUcFdWbkhqVkhVeG5fZktQbm9obVVTWHBQZEx0QldKbmozbF9sMGhRUQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-06T05:58:21+00:00", "published_display": "06 Sep 2020 05:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings (ALXO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE5HTHZUTDJfYXZRaVB0MEtjWThiNVhvQ0dhR3h0WUVyRzNhQVlGX1Q3WnI4LThsdWI3OXJyRTRtSkhUVkx4enJLNDg1MndGbVU?oc=5", "source_name": "Zacks Investment Research", "published_at": "2020-07-22T20:43:41+00:00", "published_display": "22 Jul 2020 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations", "summary": "Shelly Wong, SVP of ALX Oncology Holdings (ALXO), sold 1,404 shares of common stock at a weighted average price of $2.04 per share. This transaction was conducted to fulfill tax obligations related to the vesting of her restricted stock units. After the sale, Wong directly holds ", "url": "https://www.stocktitan.net/sec-filings/ALXO/form-4-alx-oncology-holdings-inc-insider-trading-activity-f5929062a503.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:39:56", "published_display": "06 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO - Alx Oncology Holdings Inc Options", "summary": "This article provides a detailed financial overview of Alx Oncology Holdings Inc. (ALXO), including its latest stock price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as insider and institutional ownership, pr", "url": "https://finviz.com/stock?t=ALXO&ta=1&p=d&ty=oc&b=2&r=m6&ov=list_strike&s=1", "source_name": "Finviz", "published_at": "2026-07-02T09:09:47", "published_display": "02 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com", "summary": "ALX Oncology Holdings Inc. has announced Scott Garland as the new Chairman of its Board of Directors and Michael Listgarten as General Counsel. Garland, with over 30 years in biopharmaceuticals, succeeds co-founder Corey Goodman, while Listgarten brings extensive legal experience", "url": "https://ng.investing.com/news/stock-market-news/alx-oncology-names-scott-garland-chairman-adds-general-counsel-93CH-2579990", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T09:40:05", "published_display": "01 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology's Corey Goodman resigns as Chairman and director", "summary": "Corey Goodman has resigned from his roles as Chairman and a board member of ALX Oncology, effective June 29, 2026, due to personal reasons. The company stated that his resignation was not related to any disagreements regarding operations, policies, or practices. His replacement i", "url": "https://www.tradingview.com/news/tradingview:c0b3beb55333c:0-alx-oncology-s-corey-goodman-resigns-as-chairman-and-director/", "source_name": "TradingView", "published_at": "2026-07-01T08:10:25", "published_display": "01 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules", "summary": "ALX Oncology Holdings Inc. announced an inducement stock option grant to its new General Counsel, Michael Listgarten, for 500,000 shares. This grant was made on June 29, 2026, as an inducement for his employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option", "url": "https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules/2376280/amp", "source_name": "The Manila Times", "published_at": "2026-07-01T04:56:00", "published_display": "01 Jul 2026 04:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology replaces its chairman and adds a new general counsel", "summary": "ALX Oncology (Nasdaq: ALXO) has announced significant leadership changes, appointing Scott Garland as the new Chairman of the Board and Michael Listgarten as General Counsel, effective immediately. Garland succeeds co-founder Corey Goodman, who is stepping down after over a decad", "url": "https://www.stocktitan.net/news/ALXO/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-ctxi38ps1d12.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:09:10", "published_display": "30 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair", "summary": "ALX Oncology Holdings Inc. (NASDAQ: ALXO) has announced a leadership transition, with co-founder and long-time Chairman Corey Goodman, Ph.D., stepping down for personal reasons effective June 29, 2026. Scott Garland, an existing independent director, has been appointed as the new", "url": "https://www.stocktitan.net/sec-filings/ALXO/8-k-alx-oncology-holdings-inc-reports-material-event-9816e010ee3d.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:10:25", "published_display": "30 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Appoints Scott Garland as Board Chairman", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alx-oncology-appoints-scott-garland-122354790.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:23:54+00:00", "published_display": "30 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel", "summary": "ALX Oncology Holdings Inc. has announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel. Mr. Garland, who has served on the board since November 2022, succeeds co-founder Corey Goodman, Ph.D., who is stepping down", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319582/0/en/alx-oncology-appoints-scott-garland-as-chairman-of-the-board-and-michael-listgarten-as-general-counsel.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:09:51", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology grants 500,000-share option to new general counsel", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZ3ZXdmxFMTUyV2lWOFh5UUJLNlNpenV3T20zd1p0Tm9IMnhYSTBXMXB0RWhvaGlvTDJsMGQwN0hYUFh0OWRjSDFycThnSVFvLVYxRmw3UGVnY0FZa1lsQjFRZGpoXzBjdmZaTlVpc0VCXzA3Wkt1RDBnbTJtYjJtRmVKT0U1N0pWNm5HOE9YNHkyc2tQRVRkQlVWZkplZmdpcnpLay1hTDA4LUwwT1daT2Jpd1NsMnBGcUVR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Index", "summary": "ALX Oncology Holdings Inc. (NasdaqGS: ALXO) has been added to the Russell 3000E Index, as announced on June 29, 2026. This inclusion is part of several recent additions for the company to various Russell indices, including the Russell 2000, Russell 2000 Growth Benchmark, Russell ", "url": "https://www.marketscreener.com/news/alx-oncology-holdings-inc-nasdaqgs-alxo-added-to-russell-3000e-index-ce7f5fdedd81f226", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:09:51", "published_display": "29 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc. (ALXO) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for ALX Oncology Holdings Inc. (ALXO) on NASDAQ, showing its current price of $2.23 and a 9.30% increase. The page also includes sections for analyst ratings (currently unavailable), earnings information, and promotional content for", "url": "https://stockstotrade.com/quote/ALXO", "source_name": "StocksToTrade", "published_at": "2026-06-29T18:41:37", "published_display": "29 Jun 2026 18:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNY0VSZUJqcmpuS0c4NFJnRm9KczJLSDdCZnVGY05OdHM1MkdmbjR3eGt4NVFzRUZmblpBbU9HX3l0UThZaDdIWjhuNFR3UFdmc3NWUDRxTERrSmZfbWhTdW5ELWkyeEhRR1NEZGpBR3V1U0JXN1g5cXN2TWdic0JmNWNQYjNFQlRXV3hqaEFCS3BqOFF6V2h4VHFWZU5ETV9PWnpFZVFOS1lzbXVJZURKekk1cm5kX2hnSGkzMnlnM0JabGZDSVYtU2cxVmVrVzFPREVJSlJKaVY?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:14:00+00:00", "published_display": "29 Jun 2026 12:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ALX Oncology Holdings Inc. \u2013 NASDAQ:ALXO", "summary": "This article provides the \"Price to book forward\" for ALX Oncology Holdings Inc. (NASDAQ: ALXO). It indicates that the market is closed with no current trades. The information is presented within the context of the company's financial data on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:40:18", "published_display": "29 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell Microcap Index", "summary": "ALX Oncology Holdings Inc. (NasdaqGS:ALXO) has been added to the Russell Microcap Index. The company is a clinical-stage biotechnology firm developing therapies for cancer, with its lead product candidate, evorpacept, currently in multiple clinical trials. This inclusion in the i", "url": "https://www.marketscreener.com/news/alx-oncology-holdings-inc-nasdaqgs-alxo-added-to-russell-microcap-index-ce7f5fdedd89f627", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:39:50", "published_display": "29 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline", "summary": "ALX Oncology Holdings Inc. (ALXO) stock saw an 11.73% increase, driven by upcoming participation in the 2026 Jefferies Global Healthcare Conference. The company will showcase its clinical-stage oncology pipeline, particularly lead CD47 blocker evorpacept and EGFR-targeted ADC ALX", "url": "https://www.timothysykes.com/news/alxoncologyholdingsinc-alxo-news-2026_06_28/", "source_name": "Timothy Sykes", "published_at": "2026-06-28T14:10:25", "published_display": "28 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO Rises As ALX Oncology Showcases Pipeline At Jefferies", "summary": "ALX Oncology Holdings Inc. (ALXO) surged by 11.73% after showcasing its clinical-stage pipeline, including lead CD47 blocker evorpacept and EGFR-targeted ADC ALX2004, at the 2026 Jefferies Global Healthcare Conference. Despite being a clinical-stage biotech with negative profitab", "url": "https://stockstotrade.com/news/alxoncologyholdingsinc-alxo-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T12:10:25", "published_display": "28 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ALX Oncology Holdings Inc. \u2013 NASDAQ:ALXO", "summary": "This article provides a brief mention of the \"Price to sales forward\" metric for ALX Oncology Holdings Inc. (NASDAQ: ALXO). It appears to be a stub or a financial data point from TradingView, lacking detailed analysis or contextual information. The content primarily consists of n", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:10:25", "published_display": "28 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Secures New $50 Million Loan Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQU0NyRkozeXAtWGJGYmU2dmx5QzhhV3Y2b2xrN2xEMmxMMWd6MTdSaEdxd29tMTAzMmdnbE5WeVNLaTh1V1M0YS1uRlpXdmpkRVZUdWo5aGZ4Tm5wZnVLWXNRQTR1QVJQNzFFOWpHTFVVMkVEVHREZlhGSS0tcXhxVTB6ZkhqSkF4SmxzLUtMcVJvQ0hWLVFRY04tOGJZbmN6MGF6QW1rdFBfUW40aDQ5eUdLM00yOHFST3pSdm9SYVFNQ3I1aEp1bU95TmxQNG14UFE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing", "summary": "Alx Oncology Holdings has entered into a Loan and Security Agreement with HSBC Ventures, according to an SEC filing. This agreement was made on June 25, 2026. The news was reported by Reuters via TradingView.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Y13D:0-alx-oncology-holdings-enters-loan-and-security-agreement-with-hsbc-ventures-on-june-25-2026-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-26T22:10:51", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility", "summary": "ALX Oncology Holdings Inc. (NASDAQ: ALXO) has secured a new multi-tranche term loan facility of up to $50 million with HSBC Ventures USA Inc. The company immediately drew $10 million to refinance existing debt and has access to an additional $40 million, with portions contingent ", "url": "https://www.stocktitan.net/sec-filings/ALXO/8-k-alx-oncology-holdings-inc-reports-material-event-1ecb3f3d0d77.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:10:51", "published_display": "26 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings, Inc. Actuals & Estimates (NASDAQ:ALXO)", "summary": "This article provides an overview of ALX Oncology Holdings Inc. (ALXO) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent earnings and revenue f", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T03:09:44", "published_display": "26 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for ALX Oncology Holdings Inc. (ALXO) stock, including analyst ratings, EPS and revenue metrics, and historical price performance. It covers frequently asked questions regarding the stock's current price, volatility, market cap, e", "url": "https://www.tradingview.com/symbols/NASDAQ-ALXO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:42:29", "published_display": "25 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology: Rebuilding From Critical Setbacks (NASDAQ:ALXO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNZmlNU0ZpZ2lYRkFoWVlaaXE0YjY3bzdqS0FqbVEtX1pzZDQ5UUNRaXJrbWtrREJsM3J0dkNSUzFyZnA0Sm1JUk13RkFqTmNORmRwX05mUmxqNHRGdTNsSGE1cS0ybjhJeDBYNThZWFkySlUzOWZwSVpIc3cxMTE2RVRzbGt6VDZiRjJTLVo2Z2I?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "ALX Oncology Holdings Inc (ALXO) has a weak financial status and low operating efficiency, ranking 367 out of 389 in the Biotechnology & Medical Research industry with a financial score of 5.40. The article notes that relevant financial data for Quality of Earnings, Operational E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T03:40:08", "published_display": "19 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ALX Oncology Holdings Inc's (ALXO) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports no data available for past stock splits. The piece essentially serves as a ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:39", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Institutional Confidence", "summary": "ALX Oncology Holdings Inc (ALXO) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.46%, marking a 62.05% decrease quarter-over-quarter. James Simons", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:10:39", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for ALX Oncology Holdings Inc (ALXO), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It lists the current stock price, market capitalization, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:10", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of ALX Oncology Holdings Inc's (ALXO) shareholder structure, listing major shareholders by proportion and category (e.g., private equity, investment advisor). It also presents institutional shareholding data over several quarters and rec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:10", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc (ALXO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ALX Oncology Holdings Inc (ALXO), noting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $3.00 for ALXO, with most recommending a \"Buy\" tr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alxo/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T03:11:41", "published_display": "17 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit", "summary": "ALX Oncology Holdings Inc. stockholders voted on June 10, 2026, to re-elect Class II directors Daniel Curran, Rekha Hemrajani, and Chris Takimoto, to serve until the 2029 annual meeting. Shareholders also approved the compensation of the company's named executive officers on an a", "url": "https://www.stocktitan.net/sec-filings/ALXO/8-k-alx-oncology-holdings-inc-reports-material-event-c96ebd04b635.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:48", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALXO: All voting proposals passed and clinical programs advanced, with key data expected soon", "summary": "ALX Oncology Holdings Inc. (ALXO) announced that all voting proposals, including director elections, executive compensation, and auditor ratification, were approved at their 2026 Annual General Meeting. The company also reported progress in its clinical programs, evorpacept and A", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3547239:0-alxo-all-voting-proposals-passed-and-clinical-programs-advanced-with-key-data-expected-soon/", "source_name": "TradingView", "published_at": "2026-06-10T20:39:31", "published_display": "10 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs", "summary": "", "url": "https://finance.yahoo.com/m/a70c78b0-10ce-3efa-967b-1e607d846d0e/alx-oncology-targets-key.html", "source_name": "MarketBeat", "published_at": "2026-06-04T03:02:13+00:00", "published_display": "04 Jun 2026 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (ALXO) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/0df0ab5d-7869-36f1-b2ee-27fb57e5583f/alx-oncology-%28alxo%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-01T17:23:59+00:00", "published_display": "01 Jun 2026 17:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alx-oncology-present-2026-jefferies-120000644.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdk9CcHA2Sk9GemZFUl94bUpzZUUyRnZhcDNtSkVHeGlSdFRESEpSeXJiYWNneXM3cnlMUlFKekZ2QXl4NEY1Ynh6ZFRNY2lXOUdHdE5LWExQWEctV3pqY0hqVUMxUU1uUENhWTBUb2xrczVqMU9SSDR6SE5YNS1oelNQRFF2RTJXd1hCVEd4cXJMNGZmUWFNWWhVYzlIUGlHanVNQkE3MUw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/a7a588b2-ec18-379c-be1c-8a1f4ea9d37d/alx-oncology-holdings-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-09T12:30:00+00:00", "published_display": "09 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/62d32ea5-e650-393e-8cd4-c3e746bc928d/alx-oncology-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-08T14:57:21+00:00", "published_display": "08 May 2026 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX ONCOLOGY ($ALXO) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQaGJDcmwzM1JRZFhBT1ZRTXE1WmxGN3BLTFN4VEVVRTJpNzVYU0FaVzE3VGNVU1ZjcGJ3Z0VHZ3NUS1ZaZ2lMNV82Qmtla1FtVGY0YXVybDZvMlJ5aGVMMEZiMElHZlJJbVFnT2R1RXdfTldvVlVvZFlCeTRpaWlBaE8zUjF6ZFRSbGtzdkVB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo initiates ALX Oncology stock with overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTXJwZEJxRVgwcUxhQ25JakFPRnhjczY4ald5UUpwVm5qVHc2amtfNTFETUwtUlFta2VySjgzU1FpSUppdXRIZnJUcXlRYlZGenhSRmJkbFlNdzY4TUo0SEdNRjVVeXBDYVJ4d3Q0ODNQT09FTS1UVEdwcjg2aGJ3VXI1WjJUZ3I5ZDlDOWU5VFdoTjRVWmxrX25EWjZOZTQ2elk4WkdmYjRvTklTeTNva1hiRVlReTVlQUFfT0UyZ2Q?oc=5", "source_name": "Investing.com", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNVXJHbFRMdjdBaXlGZmNSUDYwbzZkb213MlZYQldkZmFrdEtHbFRDeV91U0doUmNQMV9TeUE5MDB0dWxidWJvWXkwWFZhY0c5RzhnWTB5ZEdEMzFvMUVHWXg5dHNIZnpVRTZzX1hrOXJsVnRGTWo2THZBd3R5RHZBVC1zcm5ON19KWnBGd0o0ek1qemhRemVxLWRfTTdiTGY2SWRnODJ2OGxPQWt4c0VQdzA0RmVPQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Announces Pricing of Underwritten Offering", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNY2tCa20yZnRVeDNhM2w4V0Y2QW9UVDBjMmNXN01oTVZTRVgwX19WaEtBQmp3dlhXZGVPMjVsQTBEcEZGdGJzMVk1Y3k4X1JsMEt1NWdjMHRMZjRlcDR4THQ4dHFiaGpNTDZYSlA3RFEtU0dLS1RtMlF1Q0dBeDdDUkZTUERsREZ4TDYw?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology (ALXO) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE95UTRQcWt3SWpkZ3pRNjRQZEV3WTgycUN1V2YxLWUzbVNtTndTZkVFSXg2Wnl4dVB4ME1EYVZMZ2lMZ2Nna25FdlZ1eDNaNDRfZ1oxUUdocUNaRmt6LV85OVZfeW1JT2FL?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T15:48:12+00:00", "published_display": "09 Jul 2025 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alx Oncology Holdings (ALXO) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBLXy16N0ZLcUtaaHZFWFgtbE9yZ2x5UDB5QVh0c0NUcFdWbkhqVkhVeG5fZktQbm9obVVTWHBQZEx0QldKbmozbF9sMGhRUQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-06T05:58:21+00:00", "published_display": "06 Sep 2020 05:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALX Oncology Holdings (ALXO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE5HTHZUTDJfYXZRaVB0MEtjWThiNVhvQ0dhR3h0WUVyRzNhQVlGX1Q3WnI4LThsdWI3OXJyRTRtSkhUVkx4enJLNDg1MndGbVU?oc=5", "source_name": "Zacks Investment Research", "published_at": "2020-07-22T20:43:41+00:00", "published_display": "22 Jul 2020 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 55, "sentiment_summary": {"positive": 17, "negative": 3, "neutral": 35, "score": 55, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 19.75, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.12, "latest_week": "2026-07-10", "one_week_move": 2.7, "four_week_move": 34.5, "twelve_week_move": 27.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.025253, "market_dynamics_buy_signal": true, "relative_strength": 16.405912, "fair_value_gap": -52.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.5131, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.7% over one week, +34.5% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": ["Market Dynamics buy signal", "Value support"], "opportunities": ["Market Dynamics is showing a buy signal in the latest weekly context.", "Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "TradingKey", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "MarketBeat", "count": 3}, {"label": "The Manila Times", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 18}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.7% over one week, +34.5% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations"}], "updated_at": "2026-07-16T06:04:50.257081+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}